Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Panbela Therapeutics Inc
PBLA | US
0.00
USD-0.01
-98.20%
PBLA | US
Loading StockChartView...
About Panbela Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
12/03/2026
Close
0.00
Open
0.00
High
0.00
Low
0.00
Panbela Therapeutics Inc. a clinical-stage biopharmaceutical company together with its subsidiaries develops disruptive therapeutics for the treatment of patients with cancer. The company's lead product candidates are Ivospemin (SBP-101) which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM a combination of eflornithine (CPP-1X) and sulindac; and Eflornithine an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin (SBP-101). The company was formerly known as Sun BioPharma Inc. and changed its name to Panbela Therapeutics Inc. in December 2020. Panbela Therapeutics Inc. was incorporated in 2011 and is based in Waconia Minnesota.
View LessPBLA | US
Risk
6567.9
Sharpe
-0.01
Luna's Score
43/100
Recommendation
Sell
Luna says (PBLA | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
11204.7%1 month
6567.9%3 months
26242.7%6 months
19220.6%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
0.00
Fwd. PE
-
Price to book
3.22
Debt to equity
-0.40
Debt to assets
0.45
Ent. to EBITDA
-0.22
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-
MarketCap
1.05K
MarketCap(USD)
1.05K
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-798.16
Short ratio
0.07
Short perc.
3.07
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
2.50
Range1M
2.50
Range3M
2.50
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.07
Price X volume
0.02
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.22 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | 0.00 | 41.03 | Cheaper |
| Price to Book | 3.22 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 26,242.70 | 72.80 | Riskier |
| Debt to Equity | -0.40 | -1.23 | Expensive |
| Debt to Assets | 0.45 | 0.25 | Expensive |
| Market Cap | 1.05K | 3.66B | Emerging |
